Literature DB >> 29342268

Reduced Expression of Mismatch Repair Genes MSH6/MSH2 Directly Promotes Pituitary Tumor Growth via the ATR-Chk1 Pathway.

Shinsuke Uraki1, Hiroyuki Ariyasu1, Asako Doi1, Shintaro Kawai1, Ken Takeshima1, Shuhei Morita1, Junya Fukai2, Koji Fujita2, Hiroto Furuta1, Masahiro Nishi1, Kokichi Sugano3, Naoko Inoshita4, Naoyuki Nakao2, Shozo Yamada5, Takashi Akamizu1.   

Abstract

Context: The mechanisms of pituitary adenoma (PA) pathogenesis and proliferation remain largely unknown.
Objectives: To clarify the role of mismatch repair (MMR) genes in the molecular mechanism of PA proliferation. Design: We performed quantitative analyses by real-time polymerase chain reaction and immunohistochemistry to detect MMR gene and protein expression in human PAs (n = 47). We also performed correlation analyses of expression levels and tumor volume doubling time (TVDT; n = 31). Specifically, correlation analyses were performed between genes with significant correlation and ataxiatelangiectasia and Rad3-related (ATR) expression in cell-cycle regulatory mechanism ATR-checkpoint kinase 1 (Chk1) pathway (n = 93). We investigated the effect of reduced gene expression on cell proliferation and ATR gene expression in AtT-20ins cells and primary cultures of human PAs.
Results: Expression of mutS homologs 6 and 2 (MSH6 and MSH2) was positively associated with TVDT (R = 0.52, P = 0.003, and R = 0.44, P = 0.01), as were the corresponding protein levels. Gene expression was positively associated with ATR expression (R = 0.47, P < 0.00001, and R = 0.49, P < 0.00001). In AtT-20ins, the reduction of MSH6 and/or MSH2 expression by small interfering RNA significantly promoted cell proliferation by decreasing ATR expression. This effect was also observed in primary culture.
Conclusion: Reduction of MSH6 and MSH2 expression at the messenger RNA and protein levels could be involved in direct PA proliferation by promoting cell-cycle progression or decreasing the rate of apoptosis through interference with the function of the ATR-Chk1 pathway.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29342268     DOI: 10.1210/jc.2017-02332

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.

Authors:  Sanjit Shah; Saima Manzoor; Yehudit Rothman; Matthew Hagen; Luke Pater; Karl Golnik; Abdelkader Mahammedi; Andrew L Lin; Ruchi Bhabhra; Jonathan A Forbes; Soma Sengupta
Journal:  Neurosurgery       Date:  2022-05-13       Impact factor: 5.315

2.  Pancreatic cancer 'mismatch' in Lynch syndrome.

Authors:  Andrew E Hendifar; Brent K Larson; Rebecca Rojansky; Michelle Guan; Jun Gong; Veronica Placencio; Richard Tuli; Megan Hitchins
Journal:  BMJ Open Gastroenterol       Date:  2019-03-22

Review 3.  DNA repair in cancer initiation, progression, and therapy-a double-edged sword.

Authors:  Katarzyna Kiwerska; Krzysztof Szyfter
Journal:  J Appl Genet       Date:  2019-08-30       Impact factor: 3.240

4.  MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.

Authors:  Shinsuke Uraki; Hiroyuki Ariyasu; Asako Doi; Ken Takeshima; Shuhei Morita; Hidefumi Inaba; Hiroto Furuta; Noriaki Fukuhara; Naoko Inoshita; Hiroshi Nishioka; Naoyuki Nakao; Shozo Yamada; Takashi Akamizu
Journal:  Int J Mol Sci       Date:  2020-04-18       Impact factor: 5.923

5.  Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence.

Authors:  Jing Guo; Qiuyue Fang; Yulou Liu; Weiyan Xie; Yazhuo Zhang; Chuzhong Li
Journal:  Oncol Lett       Date:  2021-02-08       Impact factor: 2.967

6.  A genetic map of the chromatin regulators to drug response in cancer cells.

Authors:  Bo Chen; Pengfei Li; Mingyue Liu; Kaidong Liu; Min Zou; Yiding Geng; Shuping Zhuang; Huanhuan Xu; Linzhu Wang; Tingting Chen; Yawei Li; Zhangxiang Zhao; Lishuang Qi; Yunyan Gu
Journal:  J Transl Med       Date:  2022-09-30       Impact factor: 8.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.